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Purpose: Aggressive non-Hodgkin’s lymphoma
(aNHL) is associated with poor long-term survival
after relapse, and treatment is limited by a lack of
consensus regarding standard of care. Pixantrone was
studied in a randomized trial in patients with relapsed
or refractory aNHL who had failed Z2 lines of
therapy, demonstrating a signiﬁcant improvement in
complete or unconﬁrmed complete response and
progression-free survival (PFS) compared with inves-
tigators’ choice of single-agent therapy. The objective
of this study was to assess the health economic
implications of pixantrone versus current clinical
practice (CCP) in the United Kingdom for patients
with multiply relapsed or refractory aNHL receiving
their third or fourth line of treatment.
Methods: A semi-Markov partition model based on
overall survival and PFS was developed to evaluate the
lifetime clinical and economic impact of treatment of
multiply relapsed or refractory aNHL with pixantrone
versus CCP. The empirical overall survival and PFS
data from the PIX301 trial were extrapolated to a
lifetime horizon. Resource use was elicited from
clinical experts, and unit costs and utilities were
obtained from published sources. The analysis was
conducted from the perspective of the United King-
dom’s National Health Service and personal social
services. Outcomes evaluated were total costs, life-
years, quality-adjusted life-years (QALYs), and cost
per QALY gained. Deterministic and probabilistic
sensitivity analyses were conducted to assess uncer-
tainty around the results.
Findings: Pixantrone was estimated to increase life
expectancy by a mean of 10.8 months per patient*Current afﬁliation is Rosa & Co. LLC, San Francisco, California.
March 2016compared with CCP and a mean gain of 0.56
discounted QALYs. The increased health gains were
associated with an increase in discounted costs of
approximately £18,494 per patient. The incremental
cost-effectiveness ratio of pixantrone versus CCP was
£33,272 per QALY gained. Sensitivity and scenario
analyses suggest that the incremental cost-effectiveness
ratio was sensitive to uncertainty in the PFS and
overall survival estimates and the utility values asso-
ciated with each health state.
Implications: Pixantrone may be considered both
clinically effective and cost-effective for patients with
multiply relapsed or refractory aNHL who currently
have a high level of unmet need. (Clin Ther.
2016;38:503–515) & 2016 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: cost-effectiveness, non-Hodgkin’s
lymphoma, pixantrone, survival analysis.INTRODUCTION
Non-Hodgkin’s lymphomas (NHL) are a heterogeneous
group of diseases originating in various cells within the
lymphoid system.1 The clinical course of NHL ranges
from indolent to aggressive, with diffuse large B-cell
lymphoma (DLBCL) being the most common type of
aggressive NHL (aNHL). DLBCL is usually diagnosed
when the disease is widespread, with patients experi-
encing fever, fatigue, weight loss, and night sweats.2& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
503
Progressive/
relapsed disease
Stable/no
Stable/No progression
progression
Death
On initial (third-
or fourth-line)
treatment
Discontinued
initial (third- or
fourth-line)
treatment
Figure 1. Model design.
Clinical TherapeuticsFirst-line chemotherapy for patients with DLBCL
includes rituximab with cyclophosphamide, doxoru-
bicin, vincristine and prednisone.1–5 However, 50%
to 60% of patients relapse within the ﬁrst 2 years
of treatment.4 In as few as 10% of these patients,
long-term survival with conventional salvage chemo-
therapies is achieved,6 with the median survival after
ﬁrst relapse estimated at 4 to 6 months.6 There is a
lack of consensus with regard to standard of care,
with no licensed therapies for patients with multiply
relapsed or refractory NHL,4 resulting in considerable
unmet need for these patients.
Pixantrone is a novel aza-anthracenedione that was
studied in a Phase III, multicenter, open-label, random-
ized trial in heavily pretreated patients with relapsed or
refractory aNHL (ie, the PIX301 trial).7 The efﬁcacy
and safety of pixantrone dimaleate provided at a dose
of 50 mg/m2 of active substance (or 85 mg/m2)
intravenously on days 1, 8, and 15 of a 28-day cycle,
for up to 6 cycles, was examined compared with
investigators’ choice of single-agent therapy (vinorel-
bine, oxaliplatin, ifosfamide, etoposide, mitoxantrone,
or gemcitabine) given at prespeciﬁed standard doses
and schedules. Investigators’ choice of treatments is
consistent with current practice in England and Wales
and is therefore referred to as current clinical practice
(CCP) hereafter. Patients were followed up for 18
months after the last treatment for assessment of
disease progression and survival. A signiﬁcantly higher
proportion of patients treated with pixantrone achieved
a complete or unconﬁrmed complete response at the
end of treatment versus those patients receiving the
comparator drugs (20.0% vs 5.7%; P ¼ 0.021).
Progression-free survival (PFS) was signiﬁcantly higher
in the pixantrone group (hazard ratio, 0.60 [95% CI,
0.42–0.86]). Overall survival (OS) was not signiﬁcantly
longer (hazard ratio, 0.79 [95% CI, 0.53–1.18]),
despite a favorable trend observed for pixantrone.8
As in numerous other countries, the United King-
dom’s health care system requires that a new treatment
be cost-effective; that is, the costs associated with a new
treatment are balanced against its additional clinical
beneﬁts compared with currently used treatments. The
objective of the present study was to assess the health
outcomes and cost-effectiveness of pixantrone versus
CCP over a lifetime for patients with multiply relapsed
or refractory aNHL receiving third- or fourth-line
treatment from the perspective of the UK National
Health Service and personal social services.504MATERIALS AND METHODS
Model Design
A partition model was developed to estimate long-
term clinical and economic outcomes for patients with
multiply relapsed or refractory aNHL receiving third-
or fourth-line treatment with pixantrone or CCP. CCP
was assumed to comprise vinorelbine, oxaliplatin,
ifosfamide, etoposide, mitoxantrone, and gemcitabine
as included in the PIX301 trial.7
The model explored what might happen to a hypo-
thetical cohort of patients by using a set of mutually
exclusive health states: (1) stable/no progression, includ-
ing progression-free patients; (2) progressive/relapsed
disease, including living patients who have progressed;
and (3) death. Patients can enter, remain in, or move
(“transition”) between health states (Figure 1). While in
the stable/no progression health state, patients can stay
on or discontinue initial treatment. The model cycle was
set to 1 week (ie, patients can move between health
states once weekly).
It was assumed that patients start in the stable/no
progression health state on initial treatment. During
each cycle, patients in the stable/no progression health
state may remain stable and on initial treatment, or
they may discontinue treatment. Alternatively, they
can move to the progressive/relapsed health state or
die. Patients in the progressive/relapsed health state
can either remain in that state or die.
Patients were also at risk of experiencing adverse
events (AEs) while on treatment in the stable/no pro-
gression state. AEs were modeled as events with cost
and quality of life consequences. Treatment-emergentVolume 38 Number 3
N. Muszbek et al.grade 3 and 4 AEs occurring in at least 5% of the
patient population and grade 2 AEs considered im-
portant by clinical experts were included because these
were the AEs believed to have an impact on quality of
life and/or health care resource use.
This approach is appropriate for modeling chronic
disease when patients pass through a series of clearly
deﬁned and mutually exclusive health states based on
the treatment and progression. Furthermore, it has the
ability to reﬂect time-dependent parameters such as
PFS and OS through the use of survival curves
following the disease progression in this patient
population. By calculating the area under the survival
curves in each cycle, the distribution of the patient
cohort between the different health states deﬁned by
these curves can be estimated. The model structure
was validated by comparing it with earlier models8–11
that adopted a similar 3 health state structure, and
also with input from clinicians active in the area (in
accordance with modeling guidelines).12Model Inputs
Efficacy and Safety Inputs
The likelihood of moving between different health
states was estimated by using area under the curve or
partition approach facilitated by PFS and OS curves
from the PIX301 trial.7 Because OS and PFS were not
fully observed, results were extrapolated by using
survival functions that best ﬁt the patient-level data in
accordance with current guidelines.13–15 Fits using
exponential, Weibull, lognormal, log-logistic, andTable I. Statistical fit criteria for overall survival and pro
Distribution
Overall Survival
Pixantrone Arm
Current C
Practice
AIC BIC AIC
Weibull 150.530 154.354 152.149 1
Lognormal 147.214 151.038 148.035
Log-logistic 148.556 152.380 149.051 1
Generalized gamma 148.607 154.343 149.636 1
Exponential 149.103 151.015 150.823 1
AIC ¼ Akaike information criterion; BIC ¼ Bayesian informatio
March 2016generalized gamma distributions were assessed graphi-
cally by using parametric plots and with ﬁt statistics,
including the Akaike and Bayesian information criteria
(Table I). The predicted OS and PFS were also assessed
by clinical experts for external validation by comparing
these rates with the survival pattern seen in clinical
practice and determining if they make sense clinically
and biologically.14,16 The best ﬁt that was deemed
clinically plausible was the lognormal distribution,
separately ﬁtted to each arm; this technique was
subsequently used in the model base-case (Figure 2).
The Weibull distribution provided the worst ﬁt; how-
ever, due to its common use in oncology models,17
sensitivity analysis was conducted on this and other
distributions that provided a reasonable ﬁt.
Discontinuation of the initial line of treatment for
each arm by weekly cycles was obtained from the
PIX301 trial.7 Similarly, the risk and duration of AEs
were also obtained from the PIX301 trial.Utilities
In absence of utility data from the PIX301 trial and
in the literature speciﬁc to the modeled population,
patients’ quality of life (based on expert opinion) was
assumed to be similar to that of patients with second-
line advanced and/or metastatic renal cell carcinoma.18
A pre-progression utility of 0.76 (SE, 0.03) and post-
progression utility of 0.68 (SE, 0.04) were therefore
used for the base-case analysis. Sensitivity analysis was
conducted by using alternative utility values as obtained
from the published literature, including values forgression-free survival.
Progression-free Survival
linical
Arm Pixantrone Arm
Current Clinical
Practice Arm
BIC AIC BIC AIC BIC
55.933 159.164 162.988 150.382 154.166
151.819 150.907 154.731 150.358 154.142
52.834 152.022 155.846 144.687 148.471
55.312 150.601 156.337 149.399 155.074
52.714 157.649 159.561 148.382 150.274
n criteria.
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Figure 2. (A) Overall survival and (B) progression-free survival for patients with multiply relapsed or
refractory aggressive non-Hodgkin’s lymphoma (estimated from Kaplan-Meier and separately fitted
lognormal distributions from post-hoc analyses of the PIX301 trial).
Clinical Therapeuticspatients with chronic myeloid leukemia,19 chronic
lymphocytic leukemia,20 metastatic melanoma,21
follicular lymphoma,3,22,23 renal cell carcinoma,24 and
DLBCL.25 Utility decrements associated with AEs were
obtained from the published literature26–33 and were
applied for the duration observed in the PIX301 trial.
The weighted average annual utility decrements asso-
ciated with grade 2 AEs experienced with pixantrone
and CCP were calculated to be 0.0075 and 0.0066,
respectively. The average utility decrement associated
with grade 3/4 AEs experienced with pixantrone and
CCP were calculated to be 0.0078 and 0.0073.
Resource Use and Costs
Drug costs were obtained from the Electronic
Market Information Tool (eMIT),34 which provides
information about prices and usage for generic drugs
and pharmaceutical products in the United Kingdom,
and from the British National Formulary.35 If 41
brand was available, the least expensive option was
selected. Drug costs were applied assuming that vial
sharing is not common practice for any treatment due
to low patient numbers (as advised by clinicians)
(Table II). Calculation of drug costs including
wastage in the absence of vial sharing was
conducted by using the suggested method of Sacco
et al.36 In addition to the cost of chemotherapies, a
cost of administration was applied to each treatment
according to the length and timing of administration
as speciﬁed by healthcare resource groups (HRGs).37
Resource use associated with disease management
and the treatment of AEs was elicited from 3 UK506clinical experts. Speciﬁc resource use items included
health care professional contacts, subsequent therapies,
laboratory tests and imaging, inpatient stay, and
personal and social services (residential care, day care,
home care, and hospice). Disease management was
estimated separately for patients in stable/no progres-
sion state on active treatment, stable/no progression
state off active treatment, and progressive disease. Unit
costs were obtained from the National Schedule of
Reference Costs,37 the British National Formulary,35
Personal Social Services Research Unit,38 and National
Audit Ofﬁce, reported in 2011–2012 prices (Table II).Analyses
The analyses observed patients throughout their
lifetimes, estimated to be a maximum of 23 years
using the average life expectancy in the United King-
dom in the general population39 for the average age of
the patients entering the PIX301 trial. Outcomes were
estimated by calculating the life-years gained, quality-
adjusted life years (QALYs) gained, and costs accu-
mulated over the time horizon of the model per
patient. Costs and health beneﬁts were discounted at
an annual rate of 3.5%.13 The relative beneﬁt of
pixantrone versus CCP was assessed by using the
incremental cost-effectiveness ratio (ICER), which
represented the additional cost required to achieve
an additional QALY with pixantrone compared with
CCP. The effect of uncertainties associated with the
model assumptions and input parameters on model
outcomes was assessed by a combination ofVolume 38 Number 3
Table II. Key drug and disease management costs.
Description Units Price/Cost, £ Source
Drug costs
Vinorelbine 10 mg/mL; 1-mL vial 5.83 34
10 mg/mL; 5-mL vial 21.83 34
Oxaliplatin 50-mg vial 12.23 34
100-mg vial 21.46 34
Ifosfamide 1000-mg vial 43.53 35
2000-mg vial 88.62 35
Ifosfamide 50-mg capsule 4.99 35
100-mg capsule 8.72 35
Etoposide (100 mg IV) 20-mg/mL; 5-mL vial 2.09 34
20-mg/mL; 25-mL vial 7.98 34
Mitoxantrone 2-mg/mL; 10-mL vial 26.06 34
2-mg/mL; 13-mL vial 26.96 34
Gemcitabine 200-mg vial 3.22 34
1000-mg vial 12.64 34
2000-mg vial 24.70 34
Pixantrone 50-mg vial 553.50 35
Administration costs
Oral chemotherapy (applied to etoposide 50 mg) Per administration 163.00 8
Simple parenteral chemotherapy at ﬁrst
attendance (applied to pixantrone,
vinorelibine, etoposide 100 mg, mitoxantrone,
and gemcitabine)
Per administration; 30 minutes’
nurse time, 30–60 minutes’
chair time
231.00 8
Complex chemotherapy, including prolonged
infusional treatment at ﬁrst attendance
(applied to ifosfamide and oxaliplatin)
Per administration, 60 minutes’
nurse time, 42 hours’ chair
time
302.00 8
Deliver subsequent elements of a chemotherapy
cycle
Per administration 206.00 8
Costs associated with stable/no progression health state while on initial treatment
Professional and social services Per 4 weeks 476.42 38
Health care professional costs Per 4 weeks 788.96 38, 47
Treatment follow-up costs Per 4 weeks 86.63 47
Hospital costs Annual 2357.28 38, 47
Grade 2 AE costs with pixantrone Average cost* per AE 39.65 24, 35, 37
Grade 2 AE costs with CCP Average cost* per AE 43.18 24, 35, 37
Grade 3/4 AE costs with pixantrone Average cost* per AE 254.26 24, 35, 37
Grade 3/4 AE costs with CCP Average cost* per AE 385.78 24, 35, 37
Costs associated with stable/no progression health state while discontinued initial treatment
Professional and social services Per 4 weeks 119.10 38
Health care professional costs Per 4 weeks 220.38 38, 47
Treatment follow-up costs Per 4 weeks 86.63 47
Subsequent treatment costs One off/on discontinuation 1169.06 34, 35
(continued)
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Table II. (continued).
Description Units Price/Cost, £ Source
Costs associated with progressive/relapsed health state
Professional and social services Per 4 weeks 1993.89 38
Health care professional costs Per 4 weeks 990.74 38, 47
Treatment follow-up costs Per 4 weeks 18.44 47
Subsequent treatment costs One off/on progression 1723.68 34, 35
Hospital costs Annual 1982.03 38, 47
Progression costs One off on progression 798.20 35, 38
AE ¼ adverse event; CCP ¼ current clinical practice.
*Based on a weighted average of distribution of AEs and cost per each AE. Cost does not reﬂect variations in incidence.
Clinical Therapeuticsdeterministic 1-way sensitivity analyses, subgroup
analyses, scenario analyses, and probabilistic sensitiv-
ity analysis (PSA).
A 1-way deterministic sensitivity analysis was
performed in which each parameter was varied ac-
cording to its 95% CI or SE, where reported, while
holding all other parameters constant. The parameters
varied included OS, PFS, treatment discontinuation,
risk of AEs, utilities, drug costs, administration costs,
disease management costs, and AE-related costs.
To assess whether the base-case results are general-
izable across various populations with different char-
acteristics and to assess uncertainties associated with
the trial population, subgroup analyses were con-
ducted. We examined a subgroup of patients who were
classiﬁed as having aggressive disease by an independ-
ent central review (ICR), and among those, a subset of
patients who had received rituximab previously.
Scenario analyses were also performed to examine
the impact of structural and input uncertainties on
model outcomes. Each scenario was formulated by
using different assumptions for extrapolation of OS
and PFS, including use of Kaplan-Meier estimates
until trial follow-up, generalized gamma (providing
the best statistical ﬁt), and Weibull (the most com-
monly used) distributions. In addition, use of alter-
native utility value sets was tested, as well as use of
shorter time horizons.
Finally, a PSA was undertaken to gain a better
understanding of the effect of parameter uncertainty.
Inputs were assigned a probability distribution and
varied simultaneously 5000 times, with each simula-
tion producing a pair of incremental QALYs and508costs. PFS, OS, treatment discontinuation, costs, and
utilities were varied simultaneously and independently
of each other. Time horizon, discount rates, and drug
costs were excluded from the PSA because they are
not subject to parameter uncertainty. Distributions for
each parameter were assigned in accordance with
guidelines on representing parameter uncertainty40,41;
that is, a gamma distribution was applied to the costs,
the length of AEs, and the number of AEs; a normal
distribution for body surface area; a β-distribution for
utilities; and a Dirichlet distribution for subsequent
treatments. For the OS and PFS distribution parame-
ters, a Cholesky decomposition of the covariance
matrix was used40 to maintain correlation between
parameters.RESULTS
Base-case Analysis
In the base-case analysis, pixantrone was more
effective compared with CCP, increasing life expect-
ancy by a mean of 10.8 undiscounted months per
patient (33.96 vs 23.16 months). The gain in life
expectancy was primarily observed in the progression-
free state, which subsequently resulted in a discounted
incremental QALY of 0.56 (1.76 QALYs for the
pixantrone arm; 1.20 QALYs for CCP) (Table III).
Mean discounted costs incurred over the lifetime
time horizon among patients receiving pixantrone
were £84,703 per patient, £18,494 higher than pa-
tients receiving the comparator treatments. Increased
costs were primarily attributed to increased drug
acquisition and administration costs, as well asVolume 38 Number 3
N. Muszbek et al.increased costs of care in the pre-progression state,
due to extended pre-progression survival. However,
these were accompanied by cost savings in the pro-
gressed health state. The increase in both costs and
QALYs led to an ICER of pixantrone versus CCP of
£33,272 per QALY gained.
Sensitivity Analyses
Results from the 1-way sensitivity and scenario
analyses highlighted that the ICER was most sensitive
to variation in the PFS and OS estimates and the
utility value for the stable/no progression health state.
Variation in disease management costs and AE-related
costs had a smaller inﬂuence on the ICER compared
with PFS, OS, and utility estimates, and did not alter
the base-case conclusions. The ICERs observed in the
subgroup analyses were £35,326 per QALY gained in
patients classiﬁed by ICR, and £45,282 per QALY
gained in patients classiﬁed by ICR who had received
prior rituximab (Table IV). Different assumptions
regarding the extrapolation varied the ICER between
£2,468 per QALY (generalized gamma) and £40,890
per QALY (Weibull). Use of alternative utility valueTable III. Base-case results.
Variable Pixantrone
Current Best
Practice
Drug and
administration
costs, £
16,843 316
AE costs, £ 371 285
Pre-progression costs,
£
17,282 6542
Post-progression
costs, £
45,145 54,620
Total costs, £ 79,650 66,209
Total LYG 2.42 1.71
Total QALYs 1.76 1.20
Incremental costs, £ 18,494
Incremental LYG 0.71
Incremental QALYs 0.56
ICER (QALYs), £ 33,272
AE ¼ adverse event; ICER ¼ incremental cost-
effectiveness ratio; LYG ¼ life-year gained; QALY ¼
quality-adjusted LY.
March 2016sets resulted in ICERs ranging from £29,419 to
£36,961 per QALY.
The cost-effectiveness plane of the PSA highlights
that the majority of simulations were in the north-east
quadrant, suggesting that pixantrone was both more
costly and more effective than the comparator
(Figure 3). Approximately 41.50% and 83.12% of
simulations resulted in pixantrone being cost-effective
at a threshold of £30,000 and £50,000, respectively,
per QALY gained.DISCUSSION
This study assessed the cost-effectiveness of pixan-
trone versus CCP for the treatment of patients with
multiply relapsed or refractory aNHL. The analysis
expanded on the ﬁndings from the PIX301 trial,7
providing estimates on the mean gain in life
expectancy over a lifetime time horizon in patients
treated with pixantrone. Our analysis estimated that
pixantrone-treated patients experience longer life ex-
pectancy by a mean of 10.8 months (undiscounted).
This mean estimate differs from the median gain in life
expectancy reported in the PIX301 trial (2.6 months)7
as it describes the mean expected health gain of all
patients’ complete life expectancy as requested by
National Institute for Health and Care Excellence
(NICE) guidelines. Because the trial data were
collected over 18 months of follow-up, patients’
complete life expectancy data were not available.
Based on the Kaplan-Meier estimates, 35% and
25% of pixantrone- and CCP-treated patients were
alive by the end of follow-up, respectively. PFS and
OS were therefore extrapolated by using parametric
survival analyses according to guidelines from the
NICE Decision Support Unit.14 Findings of a higher
mean versus median gain in life expectancy are
common in oncology modeling.42,43 This outcome
can be attributed to patients remaining alive even
after study follow-up and a proportion of patients
experiencing longer life expectancy. Because the
median omits the additional life expectancy beyond
study follow-up, the potential full beneﬁts are not
incorporated.19,43
The predicted OS gain with pixantrone primarily
occurred pre-progression, which reduces the uncer-
tainty associated with the analysis, as a bigger pro-
portion of time pre-progression is usually measured
within the trial, while time post-progression requires509
Table IV. Scenario analysis results.
Description of Data Sources
ICER (£/QALY),
Discounted
Alternative utility scenarios (Base case: pre-progression,0.76; post-progression, 0.68)
Pre-progression 0.85, post-progression 0.73 (CML, second-line for dasatinib,
nilotinib, and imatinib)20
29,419
Pre-progression 0.65, post-progression 0.47 (CLL, third-line for ofatumumab)20 36,961
Pre-progression 0.80, post-progression 0.76 (metastatic melanoma, second-line
metastatic)53
32,151
Pre-progression 0.78, post-progression 0.62 (follicular lymphoma, ﬁrst-line
maintenance for rituximab)3,21,23
31,452
Pre-progression 0.70, post-progression 0.59 (renal cell carcinoma, ﬁrst-line metastatic
for pazopanib)24
35,561
Pre-progression 0.81, post-progression 0.6 (DLBCL, ﬁrst- and second-line for CHOP
and R-CHOP)25
29,804
Population of subgroups (base-case: ITT third- and fourth-line)
Patient treated with third- or fourth-line, histologically conﬁrmed by ICR 35,326
Patient treated with third- or fourth-line, histologically conﬁrmed by ICR, who had
received previous rituximab
45,282
Distribution used for OS and PFS (base case: lognormal distribution)
Kaplan-Meier estimates followed by lognormal distribution 27,375
Generalized Gamma distribution 2,468
Weibull distribution 40,890
Time horizon
5-year 35,347
10-year 31,905
PAS 24,181
CHOP ¼ cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL ¼ chronic lymphocytic leukemia; CML ¼ chronic
myeloid leukemia; DLBCL ¼ diffuse large B-cell lymphoma; ITT ¼ intention-to-treat; ICER ¼ Incremental cost-effectiveness
ratio; ICR ¼ independent central review; OS ¼ overall survival; PAS ¼ patient access scheme; PFS ¼ progression-free survival;
QALY ¼ quality-adjusted life year; R-CHOP ¼ CHOP plus rituximab.
Clinical Therapeuticsextrapolation. This ﬁnding contrasts with those of
many other oncology drugs for which the majority of
the beneﬁt is estimated to be post-progression.44,45
This ﬁnding is, however, supported by previous
economic models of treatments in hematology, which
reported on treatments to increase life expectancy
in a better health state, usually pre-progression.46,47
Increased life expectancy in a better health state
may be correlated with a signiﬁcantly higher propor-
tion of pixantrone-treated patients achieving complete
and unconﬁrmed complete response in the PIX301
trial.7510The increased health beneﬁts observed for pixan-
trone were accompanied by increased costs, mainly
higher drug acquisition and pre-progression costs
(including administration) that were partly due to
the added cost of pixantrone and partly because the
delayed progression required longer disease follow-up.
However, due to the gain in life expectancy being
primarily pre-progression, there was a small cost
offset in the postprogression state, during which costs
are usually higher.
The estimated ICER of £33,272 per QALY gained is
lower than ICERs typically estimated for life-extendingVolume 38 Number 3
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Figure 3. Cost-effectiveness plane: pixantrone versus current clinical practice. Each of the dots in the
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(QALYs) for pixantrone versus current clinical practice as generated by the probabilistic sensitivity
analyses. For observations that fall to the right of the solid lines, pixantrone is a cost-effective
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N. Muszbek et al.treatments in the United Kingdom. The commonly used
threshold for these type of treatments has been £50,000
per QALY gained (higher than the standard threshold
of £20,000–£30,000 per QALY) if the following criteria
are met: (1) the treatment is indicated for patients with a
short life expectancy (o24 months); (2) it extends life
by at least 3 months compared with current National
Health Service treatment; (3) it is licensed or indicated
for small patient populations; and (4) estimates are
considered plausible, objective, and robust.48 Although
the ﬁrst 3 criteria are met by pixantrone due to the
small patient population, uncertainty in the estimates
play an important role. If considered under the end-of-
life criteria, pixantrone is highly cost-effective. In the
United Kingdom, there is also a patient access scheme
(PAS) in place for pixantrone, which decreased the
estimated ICER to £24,181 per QALY gained.49 With
the PAS in place, pixantrone was cost-effective at the
commonly adopted UK threshold of £20,000 to
£30,000 per QALY gained.
The model included in the study was used in the
technology appraisal of pixantrone by NICE, and it
received a positive recommendation.49 The ICER
estimated in the base-case analysis of this study differs
from that reported in the ﬁnal NICE appraisal, in
which the cost-effectiveness estimate was limited toMarch 2016patients with an ICR-conﬁrmed diagnosis who were
receiving third- or fourth-line treatment and had
previously received rituximab. The rationale for using
this subset of patients was based on several factors as
identiﬁed by NICE during the appraisal.50 It was
believed that most patients treated in the United
Kingdom would receive rituximab before the third-
or fourth-line treatment, whereas in the PIX301 study,
only 55% of patients received prior rituximab (it only
became available for this indication during the study
in some countries and was not available in all
regions).7 In addition, NICE limited the population
to patients who were conﬁrmed to have aggressive
disease by an ICR, despite all patients in the PIX301
trial being histologically conﬁrmed on-site for aggres-
sive disease. Classiﬁcation of the lymphoma according
to retrospective ICR was not conducted in all patients
because there was either no sample or insufﬁcient
sample for this assessment.7 Our analysis focused on
the intention-to-treat population receiving third- or
fourth-line treatment, consistent with the European
licensing for pixantrone.51 However, a subgroup
analysis was conducted to assess these assumptions
and aid in the projection of the health economic
beneﬁts of pixantrone across populations. Limiting
the patient population to those who were conﬁrmed511
Clinical Therapeuticsby ICR increased the ICER by 6% compared with the
base-case. Additional subgroup analysis on patients
with previous rituximab experience suggested an
additional 28% increase in the ICER to £45,282 per
QALY gained. The ICER from this subgroup had a
higher uncertainty due to the smaller patient popula-
tion; however, both scenarios resulted in an ICER
below the threshold of £50,000 per QALY gained and
below £30,000 per QALY gained when the PAS was
considered by NICE.
As with all economic evaluations, our analysis is
subject to a number of limitations. The PIX301 trial
was considered to represent the best available evidence
to assess pixantrone.7 However, due to the small
multiply relapsed aNHL patient population eligible
for systemic treatment and the resulting slow accrual
of patients, a relatively small sample size (140 rando-
mized patients) was available for the comparison of
pixantrone monotherapy versus other single chemo-
therapy agents in third and subsequent lines of treat-
ment. Although this factor is an important source of
uncertainty in the evaluation, this was reﬂected in the
PSA by varying clinical parameters obtained from the
PIX301 trials based on their variance–covariance
matrices. The PSA results suggest pixantrone had the
highest probability of being cost-effective at thresholds
of £35,000 per QALY gained and higher. In addition,
the comparator arm in the PIX301 trial was assumed
to represent clinical practice, an assumption that was
validated with UK clinicians. This ﬁnding may not be
generalizable to all settings, however, given the lack of
consensus among clinicians regarding third and
subsequent lines of therapy.
Other limitations and areas of future research stem
from the paucity of data speciﬁc to this population.
Relevant health-related quality of life data were not
available in the PIX301 trial or in the published
literature; as a result, these data in patients with
advanced and/or metastatic renal cell carcinoma
treated with second-line agents18 were used in this
study, as accepted by the NICE Appraisal
Committee.50 However, scenario analyses with a
range of utility value sets did not alter the
conclusions of the analysis. In addition, a recent
economic evaluation in patients with relapsed or
refractory aNHL, which used the Functional
Assessment of Cancer Therapy–General quality-of-
life instrument to derive utilities, found that the utility
varied from 0.801 to 0.705 from baseline and after 2512cycles of chemotherapy.52 A weighted average of these
values results in a utility value of 0.765, consistent
with our base-case utility estimate of 0.76, indicating
that the utility value used in the model was
reasonable.CONCLUSIONS
To the best of our knowledge, this study is the ﬁrst to
assess the cost-effectiveness of pixantrone and extrap-
olate the PIX301 results7 to provide estimates of mean
overall gain in life expectancy. Furthermore, it is the
ﬁrst study to examine the health and economic effects
of treatments in patients with multiply relapsed or
refractory aNHL from the perspective of the UK
National Health Service. The analysis shows that
pixantrone may be considered to be both a clinically
effective and a cost-effective treatment for patients
with multiply relapsed aNHL, a disease with a high
level of unmet need.ACKNOWLEDGMENTS
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